Hemostemix Inc.

Clinical biotech company with autologous stem cell therapies for vascular diseases.
Current Price
$0.075
TSXV: HEM | 15.08.2025 10:40:47

Overview – Hemostemix

Hemostemix (TSXV: HEM, OTCQB: HMTXF, FSE: 2VF0) develops autologous, blood-based cell therapies (ACP-01) for the treatment of peripheral artery disease, critical limb ischemia, heart failure, and vascular dementia. The therapy is based on over 15 years of clinical experience with almost 500 treated patients and strong IP protection (91 patents).

Mines & Projects

Company Data

A2QQGU Copied!
CA4236943060 Copied!

News & Analyses – Hemostemix

1 2 3 4
News Alert

Don't Miss any News from Hemostemix and get Notified Anytime!

Videos & Interviews – Hemostemix

Mines & Projects – Hemostemix

Overview

Project Data

Hemostemix Stock

TSXV: HEM

HEM is clinically active in the biotech sector with a focus on vascular therapies. With ongoing studies for ACP-01 in vascular dementia, a continuous patent strategy, and a recent private placement of USD 336,500, the stock offers excitement for early-stage investors.

Note: This page is regularly updated to provide you with the latest developments.

Financial Data

A2QQGU Copied!
CA4236943060 Copied!

Newsletter

Don't Miss any News from Hemostemix – Subscribe to the News Alert and get Notified Anytime!

Frequently Asked Questions about Hemostemix

What is ACP-01?

ACP-01 is an autologous cell therapy derived from the patient’s own blood, developed for the regeneration of ischemic tissue. Clinical data show up to 27% improved heart function and 93.5% avoidance of amputations in CLTI.

Clinically active – Phase II data, expansion into vascular dementia through partnership with FireFly Neuroscience (AI monitoring). Approval in Germany (TERMIS 2025) and private placement signals progress.

Capital sources include participation by PatentVest, private placement in spring 2025 (≈ USD 336,500), and sale of convertible bonds (USD 517,230), with a focus on financing until the end of the phase.

End of 2024: Cash CA$705,700, annual loss CA$2.6M, deficit CA$65.9M, working capital deficit CA$1.78M. “Going concern” note indicates capital requirements for further growth.

Diese Aktie ist bei folgenden Brokern handelbar:

Über die folgenden Broker können Sie ein Depot eröffnen und anschließend die Aktie bequem handeln. Bei Klick werden Sie zum jeweiligen Anbieter weitergeleitet. Manche Links sind Partnerlinks – für Sie entstehen keine zusätzlichen Kosten.

This stock is tradable at the following brokers:

You can open an account with the following brokers and then easily trade the stock. Clicking will redirect you to the respective provider. Some links are affiliate links – there are no additional costs for you.